Michael Needle

Company: Cybrexa

Job title: Chief Medical Officer

Seminars:

Exploring CBX-12-101: a First-in-Human Study of CBX-12, an AlphalexTM Peptide Drug Conjugate (PDC) in Patients With Advanced or Metastatic Solid Tumors 9:00 am

• AlphalexTM peptides undergo a conformational change in acidic environments facilitating targeted delivery of highly potent anti-cancer therapeutics • Cybrexa PDCs do not require expression of any cell surface proteins • Analyzing the activity seen with 3 different schedules in multiple tumor typesRead more

day: Conference Day 2